Seeking Alpha
  • Today - Saturday, August 30, 2014

  • 11:26 AM
    • Pfenex (NYSEMKT:PFNX) Q2 results: Revenues: $3.3M (+41.4%); Operating Expenses: $2.9M (-2.1%); Operating Loss: ($2.2M) (-11.2%); Net Loss: ($2.6M) (-64.8%); Loss Per Share: ($1.67) (-60.6%); Quick Assets: $3.9M (-24.3%).
    • No financial guidance given.
    | Comment!
  • Friday, August 29, 2014

  • 4:28 PM
    | Comment!
  • 1:00 PM
    • Low expectations and a high short interest (11.9M shares as of Aug. 15) are proving a good mix for Veeva (VEEV +18.1%) following its FQ2 beat and guidance hike. Several firms have raised their targets.
    • Workday (WDAY +5.5%), which sold off yesterday (and took peers down with it) following its FQ2 report, is following Veeva higher. As are Veeva partner Salesforce (CRM +2.1%) and several other cloud software names. NOW +2.9%. CTCT +3.4%. JIVE +2.5%. CSOD +2%. ULTI +1.9%. MKTO +1.9%.
    • "We like [Veeva's] momentum with new products, the pace of customer deployments, and view the second-half guidance as likely conservative," says Deutsche (Buy).
    • Pac Crest (Outperform) likes the fact Veeva's billings and subscription revenue each rose over 60% Y/Y, and that its large deal activity also grew. It sees a $5B addressable market for life sciences CRM/content management software.
    | 2 Comments
  • 11:03 AM
    • Avago (AVGO +8.1%) has received a slew of target hikes after beating FQ3 estimates, reporting strong margins, and issuing healthy FQ4 guidance. RF component peers Skyworks (SWKS +1.6%), RF Micro (RFMD +4.5%), and TriQuint (TQNT +5.2%) are also higher.
    • "We believe Street continues to under-appreciate this self-help story where mgmt has a proven record of cutting costs, paying down debt, and executing on multiple secular growth cycles," says BofA/Merrill. Its FY14 and FY15 EPS forecasts have respectively been raised by 20% and 25%.
    • Credit Suisse: "Avago's leverage to structural growth drivers including content increases in the Industrials/autos end-mkts and accelerating demand for bandwidth, as well as, product cycles (4G/LTE wireless ramps at Apple and China) should allow the company to outperform peers." The diversification provided by the LSI deal is seen providing "further stability."
    • Morgan Stanley expresses "high conviction in management's ability to execute on driving LSI's [operating margin] from 17% to 30% over the next few years," given Avago has doubled its op. margin to 30% since its 2005 LBO.
    • On the CC (transcript), CEO Hock Tan mentioned wireless sales are expected to rise over 60% Q/Q thanks to "the ramp of a new phone model and a North American smartphone customer" (a clear iPhone 6 reference). Demand for FBAR filters and related products in 4G phones remains strong.
    • Wired infrastructure is expected to grow at a low-single digit rate (switch/router ASIC growth offsetting flat optical component demand), and enterprise storage is expected to see mid-single digit growth excluding the PLX acquisition.
    | 1 Comment
  • 10:13 AM
    • Taylor Devices (NASDAQ:TAYD): FQ4 EPS of $0.12.
    • Revenue of $5.3M (+2.9% Y/Y).
    • Press Release
    | Comment!
  • 9:39 AM
    • DelMar Pharmaceuticals (OTCQB:DMPI) six-month results: Revenues: $0; Operating Expenses: $2.7M (-27.5%); Net Loss: ($2.8M) (+80.3%); Loss Per Share: ($0.09) (+82.4%); Quick Assets: $4.8M (+15.1%); Cash Burn: ($1.8M) (+44.9%).
    • On July 21, 2014 the BOD voted to change the fiscal year end from December 31 to June 30. The reported financial results are for the transition period.
    • No financial guidance given.
    | Comment!
  • 8:30 AM
    • BioBlast Pharma (NASDAQ:ORPNQ2 results: Revenues: $0; Operating Expenses: $1.1M (+729.9%); Net Loss: ($1.1M) (-725.2%); Loss Per Share: ($0.10) (-400.0%); Quick Assets: $4.2M (+999%); Cash Burn: ($0.7M) (-690.5%).
    • No financial guidance given.
    | Comment!
  • 8:25 AM
    • Ipsen (OTCPK:IPSEY) 1H results (€): Revenues: 638.7M (+0.8%); Operating Expenses: 355.0M (-3.8%); Operating Income: 162.0M (+12.5%); Net Income: 104.5M (+8.3%); EPS: 1.26 (+9.6%); Quick Assets: 132.0M (+0.6%); CF Ops: 54.7M (+0.4%).
    • 2014 Guidance: Specialty Care sales growth: 6 - 8% from 4 - 6%; Primary Care sales growth: (1%) - 1% from (2%) - 0%; recurring adjusted operating income margin: 17 - 18% from 16 - 17%; core operating income margin: 19 - 20% from 18 - 19%.
    | Comment!
  • 8:03 AM
    | Comment!
  • 7:55 AM
    • Pacific Therapeutics (OTCPK:PCFTF) Q2 results (C$): Revenues: 0; Operating Expenses: 149.6K (-5.0%); Net Loss: (149.6K) (+2.0%); Loss Per Share: (0.00) (+100.0%); Quick Assets: 1.9K (-98.9%); Cash Burn (1H): (143.3K) (-24.6%).
    • No financial guidance given.
    | Comment!
  • 7:44 AM
    • Unilife (NASDAQ:UNIS) fiscal 2014 results: Revenues: $14.7M (+435.5%); Operating Expenses: $66.1M (+3.6%); Net Loss: ($57.9M) (+8.4%); Loss Per Share: ($0.59) (+24.4%); Quick Assets: $8.4M (+45.9%); Cash Burn: ($33.0M) (+20.2%).
    • No financial guidance given.
    | Comment!
  • 7:11 AM
    • Ocular Therapeutix (NASDAQ:OCUL) Q2 results: Revenues: $0.1M; Operating Expenses: $6.0M (+102.2%); Net Loss: ($6.4M) (-106.4%); Loss Per Share: ($2.10) (-76.5%); Quick Assets: $19.9M (+13.9%).
    • No financial guidance given.
    | Comment!
  • 6:56 AM
    • Big Lots (NYSE:BIG) reports comparable-store sales rose 1.7% in Q2.
    • Gross margin rate flat compared to a year ago at 39.3%.
    • SG&A expense ratio +60 bps to 34.5%.
    • Inventory -12.6% to $799M.
    • Guidance: FY14 EPS outlook to $2.40-$2.50 vs. $2.35-$2.50 prior and $2.47 consensus.
    | Comment!
  • 6:24 AM
    • Ocular Therapeutix (NASDAQ:OCUL): Q2 EPS of -$2.10 beats by $0.16.
    • Revenue of $0.1M in-line.
    • Press Release
    | Comment!
  • 6:22 AM
    • Big Lots (NYSE:BIG): Q2 EPS of $0.31 beats by $0.01.
    • Revenue of $1.20B (+1.7% Y/Y) in-line.
    • Press Release
    | Comment!
  • Thursday, August 28, 2014

  • 5:30 PM
  • 5:21 PM
    • OmniVision (NASDAQ:OVTI) is guiding for FQ2 revenue of $360M-$390M and EPS of $0.43-$0.59, in-line with a consensus of $374.5M and $0.49.
    • FQ1 gross margin was 21.7%, up from 20.1% in FQ4 and 17.4% a year ago. GAAP opex +17% Y/Y to $56.3M. Cash/short-term investments rose by $73.2M Q/Q to $524.2M (compares with a market cap of $1.6B).
    • Both mobile and automotive demand fueled the FQ1 beat. OmniVision says it's "ramping up multiple members" of its high-end PureCel image sensors for mobile clients.
    • No update is given in the earnings release on OmniVision's review of a $29/share non-binding offer from a Chinese group led by Hua Capital. Shares are at $27.73 AH.
    • FQ1 results, PR
    | Comment!
  • 5:08 PM
    • Bona Film Group (NASDAQ:BONA): Q2 EPS of $0.05 beats by $0.01.
    • Revenue of $44.9M (+58.9% Y/Y) beats by $0.8M.
    • Press Release
    | Comment!
  • 5:00 PM
    • Though Avago's (NASDAQ:AVGO) revenue from continuing ops of $1.29B was below consensus, the figure excludes sales from its flash storage product unit (to be sold to Seagate) and its Axxia network processor unit (to be sold to Intel). With flash/Axxia included, revenue was $1.39B, above a $1.35B consensus.
    • FQ4 guidance, which excludes flash/Axxia but includes just-acquired PLX Technology, is for revenue from continuing ops to be up 18%-22% Q/Q. The consensus is at $1.42B.
    • FQ3 gross margin for continuing ops was 57%, up from 54% in FQ2 and 51% a year ago. Opex was 23.9% of revenue vs. 21.2% a year ago. GM is expected to be at 56% (+/- 1%) in FQ4, and opex is expected to be flat Q/Q at $307M.
    • Thanks to LSI's products, enterprise storage made up 32% of revenue. Wireless was 28%, wired infrastructure 27%, and industrial 13%. Strong 4G RF component demand helped wireless sales rise 26% Y/Y.
    • FQ3 results, PR
    | 1 Comment
  • 4:35 PM
    • Veeva's (NYSE:VEEV) subscription revenue rose 66% Y/Y in FQ2 to $56.6M, after growing 74% in FQ1. Services/other revenue rose 23% to $19.1M.
    • The cloud pharma/life sciences software vendor saw "particular strength" for its CRM software, and added 10+ customers for its Vault content management software.
    • GAAP sales/marketing spend totaled $13.8M, R&D $9.8M, and G&A $7.1M. Veeva's deferred revenue balance rose 14% Q/Q to $85.3M.
    • FQ2 results, PR, financials
    | Comment!
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector